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D-Amino acid oxidase (DAAO; EC 1.4.3.3) has been proposed to play a
main role in the degradation of D-serine, an allosteric activator of the
N-methyl-D-aspartate-type glutamate receptor in the human brain, and to be
associated with the onset of schizophrenia. To prevent excessive D-serine
degradation, novel drugs for schizophrenia treatment based on DAAO inhi-
bition were designed and tested on rats. However, the properties of rat
DAAO are unknown and various in vivo trials have demonstrated the effects
of DAAO inhibitors on D-serine concentration in rats. In the present study,
rat DAAO was efﬁciently expressed in Escherichia coli. The recombinant
enzyme was puriﬁed as an active, 40 kDa monomeric ﬂavoenzyme showing
the basic properties of the dehydrogenase-oxidase class of ﬂavoproteins. Rat
DAAO differs signiﬁcantly from the human counterpart because: (a) it pos-
sesses a different substrate speciﬁcity; (b) it shows a lower kinetic efﬁciency,
mainly as a result of a low substrate afﬁnity; (c) it differs in afﬁnity for the
binding of classical inhibitors; (d) it is a stable monomer in the absence of
an active site ligand; and (e) it interacts with the mammalian protein modu-
lator pLG72 yielding a  100 kDa complex in addition to the  200 kDa
one, as formed by the human DAAO. Furthermore, the concentration of
endogenous D-serine in U87 glioblastoma cells was not affected by transfec-
tion with rat DAAO, whereas it was signiﬁcantly decreased when expressing
the human homologue. These results raise doubt on the use of the rat as a
model system for testing new drugs against schizophrenia and indicate a
different physiological function of DAAO in rodents and humans.
Structured digital abstract
l pLG72 binds rDAAO by molecular sieving (View interaction)
Introduction
D-Amino acid oxidase (DAAO; EC 1.4.3.3) is a FAD-
containing ﬂavoprotein that dehydrogenates the D-iso-
mer of amino acids to the corresponding a-keto acids
and ammonia, coupled with the reduction of FAD.
The cofactor then reoxidizes on molecular oxygen,
yielding hydrogen peroxide [1]. In the human brain,
Abbreviations
CBIO, 6-chlorobenzo(d)isoxazol-3-ol; CPZ, chlorpromazine; DAAO, D-amino acid oxidase; EYFP, enhanced yellow fluorescent protein;
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DAAO is involved in the degradation of D-serine, a neu-
romodulator acting as coagonist at the glycine site on
the N-methyl-D-aspartate receptor (NMDAR). D-Serine
is synthesized starting from its L-isomer by serine race-
mase (racemization reaction) and is metabolized by the
a,b-elimination reaction catalyzed by the same enzyme
and ⁄or by DAAO-catalyzed oxidative deamination [2].
Accordingly, human DAAO (hDAAO), expressed in
different brain areas, might play a key role in regulat-
ing the activity of NMDAR: indeed, NMDAR hypo-
function has been implicated in the pathophysiology of
schizophrenia [2–4]. It has been proposed that, by
increasing NMDA receptor function (e.g. by inhibiting
D-serine degradation), schizophrenic symptoms might
be ameliorated. This hypothesis is supported by various
observations: D-serine levels in serum and cerebral
spinal ﬂuid are lower in schizophrenia patients than in
healthy controls [5], whereas, in the same individuals,
DAAO activity and expression levels are increased
[6–8]. Furthermore, the oral administration of D-serine
improved positive, negative and cognitive symptoms of
schizophrenia patients as add-on therapy to typical and
atypical antipsychotics [9]. The coadministration of
D-serine with a DAAO inhibitor has been proposed as
a more effective means of increasing the concentration
of the neuromodulator in the brain [10].
This important physiological role of D-serine ⁄DAAO
coupling opened the way to the discovery of new drugs
for schizophrenia treatment based on DAAO inhibition
[10–13]: the rat has been widely used as an in vivo model
for screening and testing such novel drugs. During the
discovery of new hDAAO inhibitors by high-through-
put screening, Duplantier et al. [13] reported that, for a
number of compounds, rat DAAO (rDAAO) potencies
were 50–100-fold weaker than for hDAAO; for exam-
ple, for 3-hydroxyquinolin-2(1H)-one, Ki values were
424 and 9 nM for rDAAO and hDAAO, respectively.
This observation has been proposed to explain the high
free brain exposure required to increase in vivo D-serine
levels in the rat [13] and prompted the same authors to
choose the mouse instead of rat to evaluate the ability
of the compounds (DAAO inhibitors) to increase cere-
bellar D-serine levels.
The nucleotide sequence of rDAAO cDNA was
determined in 1998 [14]: it encodes for an enzyme of
346 amino acids, sharing 93% and 80% sequence iden-
tity with the mouse and human homologues, respec-
tively. Noteworthy, all the active site residues are fully
conserved between rat and mouse DAAOs. Among the
22 residues that differ between hDAAO and the rodent
counterparts, seven are identical between human and
rat, eight are identical between human and mouse, and
only seven are different in all three enzymes: the sub-
stitutions randomly distribute on the protein surface.
A detailed biochemical and structural characterization
of rDAAO, and a comparison with hDAAO, is crucial
for endorsing the use of rat as an animal model for
schizophrenia.
Results
Biochemical properties of recombinant rDAAO
Recombinant rDAAO was overexpressed in BL21
(DE3)Star Escherichia coli cells using the same condi-
tions previously set up for hDAAO [15] and puriﬁed
to 95% homogeneity by a single-step procedure on a
metal-chelate afﬁnity column (Fig. S1). A yield of
rDAAO of 15 mgÆL)1 culture (0.65 mgÆg)1Æcell) was
achieved.
The puriﬁed rDAAO shows the classical absorbance
spectrum of FAD-containing ﬂavoproteins, with max-
ima at 448, 368 and 274 nm (Fig. 1A, continuous line).
The A274 ⁄A448 ratio, a parameter of protein purity, is
 9.8 (e448 nm = 12.2 ± 0.4 mM)1Æcm)1). The oxidized
form of the puriﬁed enzyme is immediately converted
into the fully reduced species after adding the substrate
D-alanine under anaerobic conditions (Fig. 1A, dashed
line). Upon anaerobic photoreduction, oxidized
rDAAO converts into the corresponding anionic
semiquinone form:  90% of the one-electron reduced
form of FAD was formed (Fig. 1A, dotted line). This
species is kinetically stabilized because it is fully lost
when mixed with benzyl viologen or when incubated in
the dark overnight. The redox properties of rDAAO
are provided in Appendix S1.
rDAAO shows good thermal stability: the melting
temperature is 46.8 ± 0.2 C and 51.9 ± 0.2 C mea-
suring the changes in protein and ﬂavin ﬂuorescence,
respectively. These values also indicate that the loss of
tertiary structure precedes FAD dissociation, as also
reported for yeast DAAO [1].
Gel-permeation chromatography shows that rDAAO
is a monomer in the concentration range 1–20 mgÆmL)1
for both the holoenzyme and the apoprotein forms
(Fig. 2A), whereas hDAAO is a stable homodimer [16].
At 2, 10 and 20 mgÆmL)1 protein, the addition of
40 lM FAD does not modify the elution proﬁle of
rDAAO holoenzyme, whereas, in the presence of 1 mM
benzoate a shift to an elution volume corresponding to
an  80 kDa homodimer is observed. These results
indicate that there are signiﬁcant alterations of the
dimerization interface between the two mammalian
DAAOs (see below). This is also apparent by monitor-
ing the binding of the primate-speciﬁc modulator
pLG72 protein by gel-permeation chromatography
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[17]. A mixture comprising a ﬁxed amount of rDAAO
(25 nmol) and different amounts of pLG72 (12.5–
100 nmol) was separated on a Superdex 200 column:
the elution volume of rDAAO shifted from  16.1 mL
to 14.2 and 12.8 mL (i.e. from the monomeric state of
40 kDa to forms of  100 and 200 kDa) (Fig. 2B). The
presence of both pLG72 and hDAAO in these latter
peaks was demonstrated by SDS ⁄PAGE (Fig. 2B,
inset). Furthermore, the relative intensity of the two
peaks was similarly modiﬁed by altering the rDAAO-
pLG72 ratio and the 100 kDa complex was also appar-
ent when an excess of rDAAO was used. This observa-
tions exclude the 100 kDa complex as a precursor of
the bigger one and indicate two alternative modes of
interaction of pLG72 with rDAAO. This behaviour dif-
fers from that observed for hDAAO where an
 100 kDa complex was never produced: for the
human ﬂavoenzyme, and both using the dimeric holo-
enzyme or the monomeric apoprotein, an  200 kDa
complex comprising two pLG72 monomers and four
hDAAO monomers was the only complex formed [17].
The model of rDAAO was built using SWISSMODEL
and the 3D structure of hDAAO in complex with
3-hydroxyquinolin-2(1H)-one as the template [13]. As
expected, there were no signiﬁcant differences in the
overall tertiary structure between the two mammalian
DAAOs (Fig. 3A): a large part of the substitutions
localize on the protein surface (Fig. 3B). Focusing on
the monomer–monomer interface, three residues distin-
guish rDAAO (as well as the mouse counterpart) from
hDAAO: (a) R120 in hDAAO, involved in electro-
static interactions with the carboxylic group of D73
and hydrogen-bonded to the backbone C=O groups
of D109, T110 and V111, is replaced by S119 in
rDAAO; (b) the residue hDAAO-Q234 in rDAAO is
Fig. 1. Spectral properties of purified rDAAO. (A) Comparison of
the visible absorbance spectra of oxidized (—), fully reduced (- - -;
obtained by anaerobic addition of 310 mM D-alanine) and semiqui-
none form (. . .; obtained by light-induced anaerobic reduction) of
rDAAO. (B) Perturbation of the visible spectrum of rDAAO after the
addition of benzoate (- - -; 1.3 mM) and anthranilate (. . .; 10 mM).
Spectra were recorded in 20 mM Tris–HCl (pH 8.0), 10% glycerol
and 5 mM 2-mercaptoethanol at 15 C, and using  0.4 mgÆmL)1
protein.
Fig. 2. Analysis of pLG72 binding to rDAAO by gel-permeation
chromatography. Elution profiles of gel-permeation chromatography
of: (A) 25 nmol of purified rDAAO (—; left axis), and pLG72 (. . .;
right axis) proteins; (B) mixtures containing 25 nmol of rDAAO and
different amounts of pLG72 (25 nmol, —, or 50 nmol, - - -). Peaks
were analyzed by nonlinear curve fitting (using PEAKFIT software).
(B, inset) SDS ⁄ PAGE analysis of purified rDAAO (5 lg, lane 2) and
pLG72 (5 lg, lane 3) and of the rDAAO-pLG72 complexes isolated
by gel-permeation chromatography (lane 4, peak at 12.8 mL,
 200 kDa complex; lane 5, peak at 14.2 mL,  100 kDa complex).
Lane 1, standard proteins.
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substituted by K233; and (c) hDAAO-H78 is replaced
by C77 in rDAAO.
Steady-state kinetics
Apparent steady-state kinetic parameters of rDAAO
were determined at air saturation using the oxygen-
consumption assay on different D-amino acids and gly-
cine as substrates. As shown in Table 1, rDAAO
shows the highest afﬁnity for bulky and hydrophobic
substrates, such as D-tryptophan, D-phenylalanine and
D-proline, compared to substrates with small side
chains. Glycine is not a substrate of rDAAO (no activ-
ity was detected up to 1 M), as well as D-aspartate (no
activity up to 0.5 M). rDAAO substrate preferences
differ signiﬁcantly from those of hDAAO (Table 1)
[16]: the Km,app for D-alanine and D-serine is  100-
and 40-fold higher with respect to the human enzyme,
whereas kcat,app values are ﬁve- and two-fold higher.
The highest kinetic efﬁciency (kcat,app ⁄Km,app) deter-
mined for rDAAO is one order of magnitude lower
than for hDAAO or pig kidney DAAO (pkDAAO)
and three orders of magnitude lower than for the yeast
enzyme [1,18].
The O2-dependence of the reaction of rDAAO was
investigated by the enzyme monitored turnover method
by rapidly mixing the oxidized enzyme aerobically with
D-alanine (concentration range 1.3–10 mM) and moni-
toring the time course of spectral changes (data not
shown). The absorbance traces at 455 nm were ana-
lyzed as a function of oxygen concentration as
described previously [18]. Lineweaver–Burk plots at
different substrate concentrations show a set of parallel
lines (not shown). The same behaviour was reported
previously for pkDAAOs and hDAAOs on neutral
substrates [16,19] and, by a combination of steady-
state and pre-steady-state measurements, it was dem-
onstrated to arise from a ternary complex kinetic
mechanism with some of the rate constants sufﬁciently
small such that the bimolecular term of the steady-
state equation becomes negligible at high substrate
concentrations (Table 2). The steady-state coefﬁcients
conﬁrm the low afﬁnity of rDAAO for D-alanine, as
obtained at a ﬁxed oxygen concentration (see above),
whereas the afﬁnity for dioxygen resembles that of
known mammalian DAAOs (Table 2).
FAD binding
The apoprotein form of rDAAO was prepared by a
dialysis procedure based on the use of a high concen-
tration of a chaotropic salt (2 M KBr), with a ﬁnal
yield of  24% in terms of protein recovered. After
incubation of the apoprotein with a ten-fold molar
excess of FAD, the reconstituted holoenzyme recov-
ered  30% of the speciﬁc activity of native rDAAO.
The rDAAO apoprotein maintains the monomeric
state (see above) and the secondary structure content
Fig. 3. 3D model of rDAAO. (A) Structural overlay of the model of tertiary structure of rDAAO (purple) with the structure of hDAAO (gray,
Protein Data Bank code 3g3e): major differences in loop orientations are indicated by blue arrows and three residues of rDAAO not
conserved in hDAAO (and belonging to its monomer–monomer surface) are also indicated. (B) Surface representation of rDAAO, highlighting
(in purple) the residues that are not conserved in the human counterpart.
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of the holoenzyme (i.e. their far-UV CD spectra are
similar). Instead, signiﬁcant changes are apparent in
the near-UV CD spectrum: the holoenzyme shows a
negative peak at  270 nm that is absent in the apo-
protein (data not shown). These structural properties
of rDAAO apoprotein closely resemble those of
human and yeast DAAOs [16,20,21].
The Kd for FAD binding to rDAAO apoprotein was
determined by measuring the quenching of protein
ﬂuorescence after adding increasing amounts of the
cofactor: a value of 3.0 ± 0.8 · 10)7 M was calculated.
This value is similar to that determined for pkDAAO
(2 · 10)7 M) and  25-fold tighter than the FAD
binding to hDAAO (Table 3). Interestingly, in the
presence of benzoate, the Kd for FAD binding to
hDAAO apoprotein is signiﬁcantly lower (3 ± 1 ·
10)7 M): a similar effect of ligand binding on the cofac-
tor interaction is not apparent for rDAAO (Table 3).
Inhibitor binding
The Kd values for binding of carboxylic acids benzo-
ate, crotonate and anthranilate (well-known DAAO
inhibitors) [1] to rDAAO holoenzyme were determined
spectrophotometrically by titrating a ﬁxed amount
of rDAAO with increasing concentrations of each
compound. Binding of these inhibitors yields classical
Table 1. Comparison of substrate specificity of rDAAO and hDAAO. The apparent kinetic parameters were determined using the oxygen-
consumption assay at 25 C and pH 8.3. BD, below detection limits.
Substrate
rDAAO hDAAOa
kcat, app (s
)1) Km, app (mM) kcat ⁄ Km (mM)1Æs)1) kcat, app (s)1) Km, app (mM) kcat ⁄ Km (mM)1Æs)1)
D-Ala 27 ± 1 140 ± 20
 100b
102 ± 32c
0.20 5.2 ± 0.1 1.3 ± 0.2 4.0
D-Ser 6.4 ± 0.8 310 ± 60 0.02 3.0 ± 0.1 7.5 ± 0.5 0.4
D-Pro 47 ± 1 86 ± 22
 31b;  4.2d
68 ± 14c
0.55 10.2 ± 0.1 8.5 ± 10 1.2
D-Trp 3.7 ± 0.2 15 ± 1 0.25 3.2 ± 0.1 1.5 ± 0.1 2.1
D-Phe 8.5 ± 0.2 35 ± 9 0.24 6.6 ± 0.1 2.7 ± 0.2 2.4
Gly BD  0.9  180 0.005
a Molla et al. [16]. b Huynh et al. [30]. c Rat kidney extract. d Determined from cytophotometric analysis of pig liver sections [38].
Table 2. Comparison of steady-state coefficients of rDAAO and
hDAAO determined by rapid mixing techniques [18] at pH 8.3 and
25 C. The steady-state parameters have been determined using
the equation for a ternary complex mechanism [18,19,33]:
et ⁄ v =F0 + FD-Ala/[D-Ala] + FO2 ⁄ [O2] + UD-Ala,O2 ⁄ [D-Ala] [O2], where
kcat =1 ⁄U0; Km,D-Ala = UD-Ala ⁄U0; Km;O2 ¼ UO2 =U0; UD-Ala,O2  0.
rDAAO hDAAOa
Lineweaver–Burk plot Parallel Parallel
kcat (s
)1) 40 ± 10 14.7 ± 0.7
Km,D-Ala (mM) ‡ 100 8.8 ± 0.3
Km;O2 (mM) 0.5 ± 0.1 1.2 ± 0.3
FD-Ala (M s · 10)3) 3.3 ± 1.0 0.6 ± 0.1
UO2 (M s · 10
)5) 1.3 ± 0.2 8 ± 0.3
a Molla et al. [16].
Table 3. Comparison of binding properties of rDAAO and hDAAO.
Kd values for FAD and CPZ binding to rDAAO apoprotein were
determined by monitoring the quenching of protein fluorescence;
Kd values for inhibitors binding to rDAAO holoenzyme were deter-
mined spectrophotometrically by monitoring the perturbation of fla-
vin absorbance spectrum (for details, see Figs 1 and 4). The Ki
value determined by the oxygen-consumption assay on D-alanine as
substrate is shown in square parenthesis.
Kd
rDAAO hDAAO
FAD binding (M)
FAD (3.0 ± 0.8) · 10)7 (8.0 ± 2) · 10)6a
FAD + benzoate (3.8 ± 0.3) · 10)7 (3.0 ± 1) · 10)7a
Inhibitors binding (mM)
Benzoate 0.15 ± 0.01;  0.10b
[Ki = 0.40 ± 0.07]
0.007 ± 0.002a
Anthranilate 5.5 ± 1.2
[Ki = 1.6 ± 0.2]
0.04 ± 0.01a
Crotonate 2.9 ± 0.2 0.26 ± 0.04
CBIO 0.075 ± 0.007 0.101 ± 0.024
CPZ 0.009 ± 0.001 0.005 ± 0.0001c
Sulfite 220 ± 48 0.0064 ± 0.009a
a Molla et al. [16]. b Huynh et al. [30]. c Sacchi et al. [17]; Caldinelli
et al. [23].
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perturbations of the absorption spectrum of the
enzyme in the visible region (Fig. 1B), as previously
observed for other mammalian and yeast DAAOs [1].
The absorbance changes (at 493 nm for benzoate and
crotonate and at 550 nm for anthranilate) at increasing
concentrations of ligands show a classical saturation
behaviour and the data were ﬁt using a hyperbolic
equation (for benzoate, see Fig. 4). A weaker interac-
tion for the inhibitors tested is apparent for rDAAO
compared to the mammalian counterparts: Kd values
for benzoate and anthranilate are 20- and 130-fold
higher, respectively, than the values determined for the
human homologue (Table 3).
The oxygen-consumption assay at increasing D-ala-
nine concentrations and in the presence of different
concentrations of benzoate (0–2 mM) or anthranilate
(0–15 mM) was used to assess the mechanism of
rDAAO inhibition. Both compounds are competitive
versus the substrate because the linear ﬁt of the
experimental data obtained at different D-alanine
concentrations and ﬁxed inhibitor concentrations in
the 1 ⁄ v versus 1 ⁄ [D-Ala] double reciprocal plot con-
verge on the y-axis (for benzoate, see Fig. S2). The Ki
values resemble the Kd values obtained spectrophoto-
metrically (Table 3).
We also investigated the binding of 6-chloro-
benzo(d)isoxazol-3-ol (CBIO), which belongs to the
newly identiﬁed group of hDAAO inhibitors [10], by
measuring the perturbation of the ﬂavin absorbance
spectrum: Kd is 75 ± 7 lM. Interestingly, and in con-
trast to the classical carboxylic acid DAAO inhibitors
(see above), this compound binds rDAAO similarly to
hDAAO (Kd = 101 ± 24 lM). Indeed, the Kd value
strictly resembles the IC50 value determined previously
(189 lM) [10].
The drug chlorpromazine (CPZ), which is an ali-
phatic phenothiazine and a widely used antipsychotic
drug in the treatment of schizophrenia, possesses a
chemical structure resembling that of the isoalloxazine
ring of FAD. CPZ is known as an FAD competitive
inhibitor of pkDAAO [22] and interacts with the apo-
protein form of hDAAO, as well as with its putative
modulator pLG72, with a Kd of  5 lM [17]. The
strength of the rDAAO-CPZ interaction, as determined
following the quenching of the protein ﬂuorescence of
rDAAO apoprotein at increasing CPZ concentrations,
is similar to that determined for the human counter-
part: a Kd of 9.9 ± 1.0 lM was estimated (Table 3).
Properties of rDAAO from rat tissues
To rule out the possibility that the characterized fea-
tures of rDAAO arise from its recombinant origin and
thus differ from those of the native enzyme, the ﬂa-
voenzyme was isolated (and partially puriﬁed) from rat
kidneys. After ammonium sulfate precipitation, the
speciﬁc activity of the protein preparation was
 67 mUÆmg)1 protein, indicating that rDAAO corre-
sponds to 0.20% of the overall protein content (a
value of 0.27% was obtained by western blot analysis
of the same sample). This preparation was used to
assay the kinetics on a number of compounds: Km val-
ues were 110 ± 30 and 68 ± 14 mM for D-alanine and
D-proline, respectively (compare with values given in
Table 1 for recombinant rDAAO). This preparation
was also inactive on D-aspartate and D-glutamate (ﬁnal
concentration 0.5 M), thus conﬁrming the absence of
detectable amounts of D-aspartate oxidase. Benzoate
was demonstrated also to be a competitive inhibitor of
native rDAAO, with a Ki of 0.57 mM versus D-alanine
as substrate (Fig. S3 and Table 3). This minimal char-
acterization shows that the main kinetic and binding
properties of rDAAO puriﬁed from rat kidney strictly
resemble those of the recombinant enzyme (see above).
When the same procedure was used to isolate
rDAAO from rat brain, no DAAO-speciﬁc signal was
apparent by western blot analysis (loading up to 70 lg
of proteins; not shown), nor was any enzymatic activ-
ity detected in the crude extract. This result highlights
a very low expression of rDAAO in the brain, as also
suggested previously [14].
Fig. 4. Difference spectra for binding of benzoate to rDAAO. The
difference spectra were obtained by subtracting the absorbance
spectrum of the free oxidized form of rDAAO (10.6 lM) from the
spectrum of the same enzyme after adding 0.019, 0.0725, 0.14,
0.28, 0.62, 2.64 and 12.7 mM sodium benzoate (curves 1–7; see
the versus of the arrows), at 15 C (Fig. 1B). Inset: plot of change
in A493 as a function of benzoate concentration; continuous line: fit
based on a hyperbolic equation: DAbs = DAbstot · [benzoate] ⁄
(Kd + [benzoate]).
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Effect of rDAAO on cellular D-serine
concentration
To investigate the effect of rDAAO on the cellular level
of D-serine, we produced stably transfected U87 human
glioblastoma cells expressing enhanced yellow ﬂuores-
cent protein (EYFP)-rDAAO. The expression of the
chimeric protein was demonstrated by ﬂuorescence
microscopy, western blot analysis (Fig. 5A) and an
activity assay using the Amplex UltraRed method
(46 ± 8 mUÆmg)1 protein). The D- and L-serine concen-
trations were determined by HPLC chromatography.
Although U87 cells transfected with hDAAO showed a
statistically signiﬁcant decrease in the D ⁄ (D+ L) serine
concentration ratio compared to controls [17,23], the
overexpression of EYFP-rDAAO did not affect this
value to a statistically signiﬁcant extent (Fig. 5B).
Discussion
In 2005, a trial in the USA comprising almost 1500
patients, which aimed to test a group of anti-psychotic
drugs introduced in the 1990s, demonstrated that these
drugs were no better than perphenazine, a 50-year-old
drug that caused serious side effects. Thus, it was con-
ﬁrmed that the new drugs were almost the same as the
old ones [24]. Typical antipsychotics exert their effect
by blocking the dopamine type 2 receptor, thus affect-
ing dopamine neurotransmission. In clinical trials,
several candidate drugs are being tested that act on
receptors related to the neurotransmitter glutamate. It
is importance to note that animal tests (i.e. of memory,
attention and other aspects of cognition) are largely
employed to test drug candidates: unreliable tests may
explain why drug candidates who appear hopeful in
animal models fail in clinical use. Indeed, novel drugs
to treat schizophrenia by acting on DAAO (and hence
aim to alter D-serine metabolism) have been tested on
rats [10,11,13,25]; therefore, we decided to investigate
the properties of rDAAO.
Previous studies on rDAAO focused on its distribu-
tion not only speciﬁcally in the central nervous system
[26], but also in the peripheral nervous system [27], as
well as its cellular and subcellular distribution [26,28].
Most recently, LEA ⁄SENDAI rats lacking DAAO
activity (i.e. no DAAO mRNA was produced) have
been identiﬁed [29]. To date, the only available bio-
chemical data on rDAAO are related to a partially
puriﬁed enzyme from kidney [30]: with this enzyme
preparation, a Km,app value for D-alanine and a Ki for
benzoate similar to those reported in the present study
for recombinant rDAAO were determined (Tables 1
and 3). Analogously, our basic characterization of
rDAAO isolated from rat kidney also conﬁrms that
the properties of the recombinant enzyme resemble
those of the native protein.
Fig. 5. Dependence of D-serine concentration on DAAO stable
transfection of U87 glioblastoma cells. (A) Top: analysis of expres-
sion of chimeric fluorescent EYFP-rDAAO protein in stably trans-
fected U87 glioblastoma cells. The image was acquired by a
fluorescence microscope and shows the level and distribution of
the expressed chimeric protein. Bottom: western blot analysis per-
formed using rabbit anti-hDAAO sera confirms the expression of
EYFP-hDAAO or EYFP-rDAAO fluorescent fusion proteins in trans-
fected U87 cells. Approximately 5 · 104 cells were loaded in each
lane; as an internal control, the amount of loaded protein was
assessed using anti-a-actin serum (bottom panel). EYFP-hDAAO
(0.03 lg, left lane) recombinant purified protein was used as a posi-
tive control. (B) The histogram reports the D ⁄ (D + L) serine concen-
tration ratio in U87 cells stably transfected with EYFP-rDAAO or
EYFP-hDAAO compared to control cells. The values are expressed
as a percentage. The change in the D ⁄ (D + L) serine ratio was found
not to be significant for rDAAO versus control (P = 0.59) and signi-
ficant for hDAAO (*P < 0.00015). The data are reported as the
mean ± SE; for each point, at least six independent determinations
were performed.
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The biochemical characterization of rDAAO shows
that it differs signiﬁcantly from the human enzyme,
particularly with regard to its binding properties.
Importantly, a comparison of the hDAAO structure
with the model of rDAAO shows that all residues at
< 8 A˚ from the ligand are conserved in the two
enzymes. A comparison of the active site of human
and pig DAAOs with the model obtained for rDAAO
is depicted in Fig. S4. The hDAAO protein weakly
binds FAD, and this interaction is made ten-fold
stronger by ligand binding [16], reaching values similar
to those for uncomplexed rDAAO and pkDAAO
(Table 3). The most signiﬁcant alterations are apparent
with regard to substrate afﬁnity: Km and the kinetic
efﬁciency for D-serine are 40- and 20-fold lower,
respectively, for rDAAO than for hDAAO (Table 1).
rDAAO is the worst catalyst among the known DA-
AOs [1]: for all tested substrates, the kinetic efﬁciency
is at least one order of magnitude lower than for other
mammalian DAAOs (Table 1), whereas Km;O2 is only
marginally different (Table 2). This difference explains
the lack of an effect of rDAAO transfection in U87
cells on the cellular D-serine concentration (Fig. 5B).
Concerning the binding of carboxylic acids, binding to
rDAAO is 50–150-fold weaker than to the human (and
porcine) counterpart for all the compounds tested,
with the sole exception of the largest one (i.e. CBIO),
for which a similar afﬁnity is apparent between
rDAAO and hDAAO (Table 3). This result conﬁrms
the preference of rDAAO for the binding of bulky,
hydrophobic compounds (i.e. the lowest Km is
observed for D-tryptophan) (Table 1), and suggests
that only large, aromatic carboxylic acids could efﬁ-
ciently inhibit both rat and human DAAOs. Further-
more, the oligomeric state of rDAAO holoenzyme is
different from that of hDAAO and pkDAAOs: in solu-
tion, free rDAAO is always present as a stable mono-
mer and converts into a homodimer after the binding
of benzoate. An inspection of monomer–monomer
interaction regions between hDAAO and the model
for rDAAO (Fig. 3) indicates that the substitution of
R120 in hDAAO with S119 in rDAAO might be
mainly responsible for the weaker interaction between
monomers in the latter. Moreover, the interaction of
rDAAO with the modulator pLG72 also differs from
hDAAO [17]: an  100 kDa ensuing complex (most
likely comprising two rDAAO monomers and one
pLG72 monomer) was never observed with the human
homologue. This is an intriguing result because yeast
DAAO (which shows a different mode of monomer–
monomer interaction compared to mammalian DA-
AOs; i.e. head-to-tail versus head-to-head, respectively)
[1] does not interact with pLG72 [17]. This observation
suggests that the primate-speciﬁc pLG72 protein spe-
ciﬁcally evolved to interact with human DAAO.
In conclusion, the different properties of rDAAO
compared to hDAAO explain the observation that the
acute inhibition of rDAAO does not appear to be sufﬁ-
cient to increase D-serine concentrations to the levels
required to produce an antipsychotic and cognition-
enhancing effect in rats (i.e. as is observed after admin-
istration of high doses of exogenous D-serine) [25]
and suggest that DAAO has a different physiological
function in rodents and humans and ⁄or that different
catabolic pathways for D-serine exist. From a pharma-
cological point of view, the results obtained in the pres-
ent study raise doubts regarding the use of rat as a
model system for testing new drugs to treat schizophre-
nia and highlight the danger of applying noncritically
to humans the intriguing observation that, in rats,
DAAO might represent a target molecule for the treat-
ment of chronic pain of neuropathic origin [31].
Experimental procedures
Design, synthesis and cloning of cDNA encoding
for rDAAO
Plasmid DNA was extracted and puriﬁed using Nucleo-
Spin Extract kit (Macherey-Nagel, Du¨ren, Germany).
cDNA coding for rDAAO was a generous gift from Larry
Melnick (Sunovion Pharmaceuticals, Marlborough, MA,
USA). This cDNA was cloned into the expression plasmid
pET28 vector, carrying kanamicin resistance, using restric-
tion sites for NdeI and SalI (pET28-rDAAO): by applying
this cloning strategy, rDAAO can be expressed with a
N-terminal His-tag.
Expression and purification of recombinant
rDAAO
Recombinant rDAAO was expressed in the BL21(DE3)Star
E. coli strain, which is the best host for expressing hDAAO
[15]. Starter cultures were prepared, growing a single colony
of E. coli cells carrying the recombinant plasmid overnight
at 37 C in ﬂasks containing Terriﬁc broth (Sigma-Aldrich,
St Louis, MO, USA) to which 30 lgÆmL)1 kanamicin was
added; this culture was diluted in the same medium to a
starting value of 0.025 at D600. For preparative purposes,
2 L bafﬂed Erlenmeyer ﬂasks containing 200 mL of liquid
Terriﬁc broth medium were used. Cells were grown at
37 C with shaking (200 r.p.m.) up to the stationary phase,
when 0.6 mM isopropyl thio-b-D-galactoside was added;
cells were collected after 2 h.
Cell pellets were resuspended in freshly prepared lysis buf-
fer (3 mLÆg)1 wet cells) containing 50 mM sodium pyrophos-
phate (pH 8.3), 5% glycerol, 0.7 lgÆmL)1 pepstatin, 40 lM
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FAD, 5 mM 2-mercaptoethanol, 1.1 mM phenylmethylsul-
fonyl ﬂuoride and 10 lgÆmL)1 deoxyribonuclease I and dis-
rupted by sonication (six cycles of 30 s each, on ice, using a
Branson Soniﬁer 250; Branson Ultrasonics, Danbury, CT,
USA). The insoluble fraction was removed by centrifugation
at 39 000 g for 1 h at 4 C. Recombinant rDAAO was puri-
ﬁed up to 95% homogeneity (estimated by SDS ⁄PAGE) by
a single-step procedure on a Ni2+-chelate afﬁnity column
(HiTrap Chelating; GE Healthcare, Piscataway, NJ, USA),
equilibrated in 50 mM sodium pyrophosphate (pH 7.2), 1 M
NaCl and 5 mM 2-mercaptoethanol. A ﬁrst step at 5% of
elution buffer [50 mM sodium pyrophosphate (pH 7.2),
0.5 M imidazole, 5% glycerol and 5 mM 2-mercaptoethanol]
eliminated contaminant proteins weakly bound to the col-
umn. Then, the bound enzyme was eluted at 100% of elu-
tion buffer. The puriﬁed rDAAO was equilibrated in
storage buffer [20 mM Tris–HCl, pH 8.0, 0.1 M NaCl, 10%
glycerol (v ⁄ v) and 5 mM 2-mercaptoethanol] by gel-perme-
ation chromatography on a PD10 column (GE Healthcare)
and stored at )20 C: no loss of enzymatic activity was
observed up to 6 months.
The apoprotein form of rDAAO was produced by exten-
sive dialysis ( 40 h) of 2 mgÆmL)1 rDAAO against 50 mM
sodium pyrophosphate (pH 8.3), 2 M potassium bromide
and 1 mM EDTA. Apoprotein was then equilibrated in
50 mM sodium pyrophosphate, 10% glycerol (v ⁄ v) and
5 mM 2-mercaptoethanol.
Kinetic measurements
Steady-state kinetic measurements on different D-amino acids
as substrate were performed in 75 mM sodium pyrophos-
phate buffer (pH 8.5) at 25 C and air saturation (0.253 mM),
measuring the oxygen consumption with a Hansatech (King’s
Lynn, UK) oxygen electrode [16]. One rDAAO unit corre-
sponds to the amount of enzyme that converts 1 lmolÆmin)1
D-amino acid or oxygen. The effect of various compounds on
rDAAO activity on D-alanine as substrate was determined by
the same assay, measuring the initial reaction rate in assay
mixtures containing different concentrations of inhibitor and
substrate [32]. The initial reaction rates were used to calculate
the kinetic parameters with KALEIDAGRAPH software (Syn-
ergy Software, Reading, PA, USA).
The rapid mixing experiments were performed in 50 mM
sodium pyrophosphate buffer (pH 8.3), containing 10%
glycerol, at 25 C in a stopped-ﬂow BioLogic (Grenoble,
France) SFM-300 spectrophotometer equipped with a J&M
diode array detector (J&M Analytische Mess-und Regel-
technik GmbH, Aalen, Germany) [33]. Enzyme-monitored
turnover data were analyzed as described previously [17].
Spectroscopic experiments
All spectroscopic experiments were performed at 15 C
in 20 mM Tris–HCl (pH 8.0), 10% glycerol and 5 mM
2-mercaptoethanol. Dissociation constants for ligands were
determined spectrophotometrically by adding small volumes
(1–10 lL) of concentrated stock solutions of ligands to
samples containing 1 mL of  10 lM enzyme and calcu-
lated from the change in A493 for benzoate and crotonate,
A550 for anthranilate and A450 for sodium sulﬁte [16,34].
O2-free samples were prepared in anaerobic cuvettes by
applying ten cycles of evacuation ⁄ﬂushing with oxygen-free
argon [16]. Photoreduction experiments were carried out in
an anaerobic cuvette containing 10 lM enzyme in the pres-
ence of EDTA and 5-deaza-riboﬂavin as described previ-
ously [34]. The redox potentials for the oxidized ⁄ reduced
rDAAO couple were determined by employing the dye
equilibration method described previously [35] at 15 C.
The enzyme solution was mixed in an anaerobic cuvette
with 0.2 mM xanthine, 5 lM benzyl viologen as mediator
and 40 lM of 2-hydroxy-1,4-naphthoquinone as reference
dye: the reaction was initiated by adding 10 nM xanthine
oxidase. Data were analyzed as described previously
[35,36].
All ﬂuorescence measurements were performed at a pro-
tein concentration of 0.1 mgÆmL)1. The binding constant
for FAD was determined by titrating 1 lM apoprotein with
increasing amounts of cofactor and by monitoring reconsti-
tution measuring the quenching of protein ﬂuorescence at
340 nm (excitation at 280 nm). Temperature–ramp ﬂuores-
cence experiments were performed using a software-driven,
Peltier-based temperature controller (temperature gradient
of 0.5 CÆmin)1) [16,20].
CD spectra were recorded on a Jasco J-810 spectropola-
rimeter and analyzed using JASCO software (Jasco Europe,
Cremella, Italy). For measurements above 250 nm, the cell
path was 1 cm and, for measurements in the range 190–
250 nm, it was 0.1 cm [16].
Oligomeric state, pLG72 binding and limited
proteolysis
The oligomeric state of rDAAO (free and complexed with
pLG72) was determined by gel-permeation chromatography
on a Superdex 200 column (GE Healthcare) in 20 mM
Tris–HCl (pH 8.5), 150 mM NaCl, 5% glycerol, 5 mM 2-
mercaptoethanol and 0.06% N-lauroyl sarcosine (NLS).
The detergent was required because the solubility and the
oligomeric state of pLG72 strongly depend upon the pres-
ence of NLS [17]. The area of each peak was estimated by
nonlinear curve-ﬁtting of the elution proﬁle using PEAKFIT
software (Systat Software, Erkrath, Germany). The amount
of pLG72 and rDAAO present in the peak corresponding
to the complex was estimated by means of the intensity
of their bands after SDS ⁄PAGE, as obtained using the
software QUANTITY ONE (Bio-Rad, Hercules, CA, USA) and
a known amount of puriﬁed rDAAO [17,21].
Limited proteolysis of rDAAO holo- and apoprotein
forms (0.4 mgÆmL)1 protein) with 10% (w ⁄w) trypsin was
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carried out at 25 C in 20 mM Tris–HCl (pH 8.5), 150 mM
NaCl, 5% glycerol and 5 mM 2-mercaptoethanol as
reported previously [23,37]. For the holoenzyme only, the
experiment was also carried out in the presence of 1 mM
benzoate or 0.1 mM FAD. The results are reported in
Fig. S5 and Appendix S2.
Partial purification of rDAAO from rat tissues
Fresh rat kidneys were ﬁnely cut with a blade and homoge-
nized in 10 mM Tris–HCl buffer (pH 7.4), containing
250 mM sucrose (10 mLÆg)1 fresh kidney) with a homoge-
nizer. The sample was centrifuged at 10 000 g for 30 min at
4 C. As described previously [30], the supernatant was
fractionated by adding 50% ammonium sulfate (29.1 g per
100 mL of solution), followed by centrifugation at 39 000 g
for 1 h at 4 C. The precipitate was collected and dialyzed
overnight against 20 mM sodium pyrophosphate buffer (pH
8.3) and 10% glycerol.
Detection of cellular D- and L-serine and rDAAO
activity in U87-transfected cells
The cDNA coding for rDAAO was inserted into the pEY-
FP-C3 vector (Clontech Laboratories, Palo Alto, CA, USA)
using the HindIII and EcoRI restriction sites in-frame with
the gene coding for EYFP. U87 Human glioblastoma cells
(ATCC) were transfected by using the FuGENE HD Trans-
fection reagent (Roche, Mannheim, Germany) in accor-
dance with the manufacturer’s instructions and as described
previously [23]: 2 lg of pEYFP-C3-rDAAO eukaryotic
expression construct were used to transfect 2 · 105 cells per
well. The protein expression level was monitored using a
ﬂuorescence microscope (Olympus IX51; Olympus America,
Center Valley, PA, USA) equipped with a ﬂuorescein iso-
thiocyanate ﬁlter to detect the emission signal associated
with the ﬂuorescent tag and by western blot analysis using
anti-actin-, anti-enhanced green ﬂuorescent protein- or anti-
DAAO-speciﬁc sera. Stable clones were selected, adding
0.4 mgÆmL)1 of G418 to the growth medium [23].
The cellular D- and L-serine levels were determined by
HPLC analysis as described previously [17]. Brieﬂy,
 2.5 · 105 U87-transfected cells were resuspended in 1 mL
of ice-cold 5% trichloroacetic acid, sonicated and centri-
fuged for 30 min at 16 000 g. The soluble fraction was
extracted with water-saturated dimethylether before precol-
umn derivatization with o-phthalaldehyde ⁄N-acetyl-L-cyste-
ine in borate buffer. D- and L-serine were resolved by HPLC
chromatography on a 5 lm Waters C8 (4.6 · 250 mm)
reverse phase column (Waters Corp., Milford, MA, USA)
eluted under isocratic conditions using 0.1 M sodium acetate
buffer (pH 6.2) and 1% tetrahydrofuran at 1 mLÆmin)1 [17].
The compounds were identiﬁed on the basis of retention
times and quantiﬁed from the peak areas. The analyses were
replicated ﬁve times for each condition, and statistical anal-
yses were performed using KALEIDAGRAPH software (Syn-
ergy Software, Reading, MA, USA).
DAAO activity on crude extracts of U87 control and
EYFP-hDAAO or EYFP-rDAAO stably transfected cells
was measured by using the Amplex Ultra-Red assay kit
(Invitrogen, Karlsruhe, Germany) based on the detection of
H2O2 by the peroxidase-mediated oxidation of the ﬂuoro-
genic Amplex UltraRed dye [17,23]. Cells were suspended in
ice-cold 50 mM sodium phosphate buffer (pH 7.4), contain-
ing 1 lM pepstatin, 2 lM leupeptin and 10 lM FAD, soni-
cated for three cycles of 30 s each and centrifuged at
16 000 g for 10 min at 4 C. An aliquot of these solutions
(0.75 mL corresponding to 3 · 105 cells) was diluted 1 : 2 in
the activity assay solution containing 50 lM Amplex Ultr-
aRed, 0.2 unitsÆmL)1 horseradish peroxidase, 10 mM NaN3,
10 lM FAD and 50 mM D-alanine and incubated for 30 min
at room temperature in the dark. The reactions were
blocked by adding 20 lL of Amplex UltraRed stop reagent,
and the ﬂuorescence emission was measured at 590 nm. For
each sample, controls without the substrate D-alanine and a
sample to which 10 mM sodium benzoate (a well-known
DAAO inhibitor) was added [1] were prepared. DAAO
activity was expressed as the difference in ﬂuorescence emis-
sion between the sample and control assay mixtures. A cali-
bration curve was obtained by using known amounts of
recombinant rDAAO (range 0–20 munits).
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